Bio-Rad Laboratories (BIO.B) Financials

$234.41 0.00 (0.00%)

As of 05/2/2025

Annual Income Statements for Bio-Rad Laboratories

This table shows Bio-Rad Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	109	26	122	366	1,759	3,814	4,254	-3,628	-637	-1,844
Consolidated Net Income / (Loss)	109	26	122	366	1,759	3,814	4,254	-3,628	-637	-1,844
Net Income / (Loss) Continuing Operations	109	26	122	366	1,759	3,814	4,254	-3,628	-637	-1,844
Total Pre-Tax Income	146	42	98	513	2,261	4,918	5,449	-4,704	-850	-2,343
Total Operating Income	167	56	119	-103	230	421	500	483	338	269
Total Gross Profit	1,122	1,138	1,188	1,223	1,257	1,438	1,638	1,567	1,427	1,379
Total Revenue	2,019	2,068	2,160	2,289	2,312	2,546	2,923	2,802	2,671	2,567
Operating Revenue	2,019	2,068	2,160	2,289	2,312	2,546	2,923	2,802	2,671	2,567
Total Cost of Revenue	898	930	972	1,066	1,055	1,108	1,284	1,235	1,244	1,188
Operating Cost of Revenue	898	930	972	1,066	1,055	1,108	1,284	1,235	1,244	1,188
Total Operating Expenses	955	1,083	1,068	1,326	1,027	1,017	1,138	1,085	1,089	1,110
Selling, General & Admin Expense	762	815	807	835	825	799	877	828	842	814
Research & Development Expense	193	206	250	199	203	218	261	257	247	296
Total Other Income / (Expense), net	-21	-14	-21	616	2,031	4,497	4,949	-5,187	-1,188	-2,612
Interest Expense	22	23	23	24	23	22	1.55	38	49	49
Interest & Investment Income	-	-	-	-	2,031	4,496	4,926	-5,194	-1,252	-2,657
Other Income / (Expense), net	0.83	9.22	1.57	640	24	23	24	45	114	94
Income Tax Expense	37	16	-24	147	502	1,104	1,195	-1,077	-213	-498
Basic Earnings per Share	$3.74	$0.88	$4.12	$12.25	$58.93	$128.13	$142.61	($121.79)	($21.82)	($65.36)
Weighted Average Basic Shares Outstanding	29.19M	29.44M	29.66M	29.84M	29.84M	29.77M	29.83M	29.79M	29.21M	28.21M
Diluted Earnings per Share	$3.71	$0.88	$4.07	$12.10	$58.27	$126.47	$140.83	$0.00	$0.00	$0.00
Weighted Average Diluted Shares Outstanding	29.41M	29.65M	30.03M	30.23M	30.18M	30.16M	30.21M	29.79M	29.21M	28.21M
Weighted Average Basic & Diluted Shares Outstanding	29.36M	29.58M	-	29.80M	29.93M	29.84M	29.93M	29.60M	28.52M	28.01M

This table shows Bio-Rad Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-163	828	69	-1,162	106	350	384	-2,165	653	-716
Consolidated Net Income / (Loss)	-163	828	69	-1,162	106	350	384	-2,165	653	-716
Net Income / (Loss) Continuing Operations	-163	828	69	-1,162	106	350	384	-2,165	653	-716
Total Pre-Tax Income	-207	1,091	85	-1,500	137	428	491	-2,786	862	-909
Total Operating Income	95	119	62	90	91	95	45	101	64	58
Total Gross Profit	373	397	362	362	336	366	326	355	356	342
Total Revenue	681	730	677	681	632	681	611	638	650	667
Operating Revenue	681	730	677	681	632	681	611	638	650	667
Total Cost of Revenue	308	333	314	319	296	315	285	283	294	326
Operating Cost of Revenue	308	333	314	319	296	315	285	283	294	326
Total Operating Expenses	278	278	301	273	245	271	281	254	291	284
Selling, General & Admin Expense	211	212	226	208	201	207	215	195	200	204
Research & Development Expense	67	66	75	65	44	64	66	59	91	80
Total Other Income / (Expense), net	-302	973	23	-1,590	46	333	446	-2,888	797	-967
Interest Expense	12	12	12	12	12	12	12	12	12	12
Other Income / (Expense), net	-290	6,178	35	-1,578	59	1,598	459	-2,876	809	1,702
Income Tax Expense	-45	264	16	-338	31	79	107	-621	208	-193
Basic Earnings per Share	($5.48)	$27.24	$2.33	($39.59)	$3.65	$11.79	$13.46	($76.26)	$23.37	($25.93)
Weighted Average Basic Shares Outstanding	29.73M	29.79M	29.60M	29.36M	29.10M	29.21M	28.52M	28.40M	27.95M	28.21M
Diluted Earnings per Share	($5.48)	$117.98	$2.32	($39.59)	$3.64	$33.63	$13.45	($76.26)	$23.34	$39.47
Weighted Average Diluted Shares Outstanding	29.73M	29.79M	29.75M	29.36M	29.22M	29.21M	28.54M	28.40M	27.99M	28.21M
Weighted Average Basic & Diluted Shares Outstanding	29.82M	29.60M	29.61M	29.08M	29.15M	28.52M	28.52M	27.87M	28.00M	28.01M

This table details how cash moves in and out of Bio-Rad Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	44	-1.65	-194	-229	-229	-618	-196	-216	-30	85
Net Cash From Operating Activities	0.74	216	-18	285	0.29	585	669	18	375	455
Net Cash From Continuing Operating Activities	0.74	216	-18	7.60	0.29	-25	672	18	375	455
Net Income / (Loss) Continuing Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Cash Adjustments To Reconcile Net Income	0.74	-49	-18	7.60	0.29	-25	672	18	367	435
Changes in Operating Assets and Liabilities, net	-	265	-	-	-	-	-	-	8.20	20
Net Cash From Investing Activities	-167	-214	-176	-187	-209	-70	-797	-1,208	20	-160
Net Cash From Continuing Investing Activities	-167	-214	-176	-187	-209	-70	-797	-1,208	20	-137
Purchase of Property, Plant & Equipment	-116	-141	-115	-130	-99	-109	-134	-113	-157	-166
Acquisitions	-1.37	-0.14	-	0.00	-79	-97	-126	-101	0.00	0.00
Purchase of Investments	-299	-293	-360	-371	-371	-248	-1,305	-2,060	-689	-1,277
Sale of Property, Plant & Equipment	0.08	0.40	0.09	4.32	0.13	0.07	0.05	0.20	0.20	0.10
Divestitures	-	-	-	7.23	0.00	12	0.00	1.40	2.50	0.00
Sale and/or Maturity of Investments	249	220	300	302	332	368	767	1,066	863	1,305
Other Investing Activities, net	-	0.00	-	-0.00	8.82	3.41	0.00	-1.50	0.00	0.00
Net Cash From Financing Activities	8.58	9.02	0.34	-49	-23	-523	-55	974	-426	-219
Net Cash From Continuing Financing Activities	8.58	9.02	0.34	-49	-23	-523	-55	974	-426	-219
Repayment of Debt	-0.28	-0.30	-0.35	-2.96	-1.13	-427	-3.02	-0.50	-0.50	-1.00
Repurchase of Common Equity	0.00	0.00	-2.92	-49	-28	-100	-50	-216	-429	-204
Issuance of Common Equity	8.24	11	15	14	17	20	21	18	19	19
Other Financing Activities, net	0.63	-1.99	-11	-11	-11	-16	-23	-14	-15	-33

This table details how cash moves in and out of Bio-Rad Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-97	-128	-66	-198	-13	247	-43	-151	-128	408
Net Cash From Operating Activities	-	18	0.00	-24	24	375	0.00	-23	23	455
Net Cash From Continuing Operating Activities	-	18	0.00	-24	24	375	0.00	-23	23	455
Net Cash From Investing Activities	-88	-59	-70	28	-9.50	72	-43	-31	-56	-31
Net Cash From Continuing Investing Activities	-88	-59	-70	28	-9.50	72	-43	-31	-56	-7.14
Purchase of Property, Plant & Equipment	-28	-35	-36	-35	-44	-42	-40	-42	-40	-43
Acquisitions	-101	0.05	-	-	-	-	-	-	-	23
Purchase of Investments	-329	-253	-204	-138	-196	-151	-406	-248	-399	-223
Sale of Property, Plant & Equipment	0.01	0.09	0.00	0.04	0.07	0.10	0.03	0.07	0.06	-0.05
Sale and/or Maturity of Investments	369	231	169	201	231	263	404	259	407	235
Net Cash From Financing Activities	-8.77	-87	4.31	-203	-27	-201	0.02	-97	-96	-26
Net Cash From Continuing Financing Activities	-8.77	-87	4.31	-203	-27	-201	0.02	-97	-96	-26
Repayment of Debt	-0.11	-0.13	-0.12	-0.12	-0.12	-0.15	-0.74	-0.12	-0.12	-0.02
Repurchase of Common Equity	-	-91	0.00	-207	-21	-200	-4.75	-101	-98	-0.01
Issuance of Common Equity	4.77	4.38	4.42	5.10	4.65	4.33	5.51	4.68	5.10	3.91
Other Financing Activities, net	-13	-0.12	-	-	-9.81	-4.78	-	-	-3.13	-30

This table presents Bio-Rad Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	3,710	3,851	4,273	5,611	8,009	12,973	17,799	13,502	12,299	9,364
Total Current Assets	1,778	1,845	1,977	2,023	2,180	2,140	1,990	3,158	3,048	3,030
Cash & Equivalents	458	456	384	432	661	662	471	434	404	488
Restricted Cash	4.21	4.56	5.56	5.60	5.56	5.56	5.56	5.56	5.60	0.00
Short-Term Investments	329	383	371	413	454	329	399	1,356	1,203	1,176
Accounts Receivable	391	372	465	392	372	419	424	495	489	453
Inventories, net	490	525	595	584	554	622	572	719	781	760
Prepaid Expenses	94	91	146	187	102	91	109	124	140	123
Other Current Assets	11	12	10	9.62	11	11	10	24	26	31
Plant, Property, & Equipment, net	438	489	493	509	499	491	512	499	529	528
Total Noncurrent Assets	1,494	1,517	1,803	3,079	5,329	10,341	15,297	9,845	8,722	5,806
Long-Term Investments	720	831	1,028	2,656	4,638	9,561	14,387	8,831	7,698	4,839
Goodwill	496	477	506	220	264	292	347	406	414	411
Intangible Assets	214	162	174	133	146	199	254	332	321	294
Other Noncurrent Operating Assets	65	48	95	70	282	289	309	276	290	262
Total Liabilities & Shareholders' Equity	3,710	3,851	4,273	5,611	8,009	12,973	17,799	13,502	12,299	9,364
Total Liabilities	1,219	1,271	1,343	1,591	2,254	3,093	4,114	3,886	3,558	2,795
Total Current Liabilities	441	471	503	451	905	632	681	569	523	468
Short-Term Debt	0.30	0.33	0.42	0.49	426	1.80	0.49	0.47	0.50	1.20
Accounts Payable	122	133	135	122	107	139	142	135	145	122
Current Deferred & Payable Income Tax Liabilities	29	28	40	56	8.76	23	10	32	36	31
Current Employee Benefit Liabilities	158	163	172	144	180	223	277	195	140	124
Other Current Liabilities	102	115	127	101	122	168	164	206	202	189
Total Noncurrent Liabilities	778	800	840	1,140	1,348	2,461	3,433	3,318	3,035	2,327
Long-Term Debt	434	434	435	439	14	12	11	1,198	1,199	1,200
Noncurrent Deferred & Payable Income Tax Liabilities	233	225	222	553	998	2,077	3,065	1,770	1,476	818
Other Noncurrent Operating Liabilities	111	141	183	148	337	372	358	350	361	309
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,491	2,579	2,930	4,020	5,755	9,880	13,685	9,615	8,741	6,569
Total Preferred & Common Equity	2,491	2,579	2,930	4,020	5,755	9,880	13,685	9,615	8,741	6,569
Preferred Stock	0.00	0.00	0.00	0.00	7.50	0.00	0.00	-	0.00	0.00
Total Common Equity	2,491	2,579	2,930	4,020	5,755	9,880	13,685	9,615	8,741	6,569
Common Stock	300	333	361	394	410	429	442	447	449	463
Retained Earnings	1,808	1,829	1,830	3,722	5,471	9,268	13,525	9,898	9,261	7,416
Treasury Stock	-0.10	-0.10	-0.22	-49	-38	-100	-106	-264	-633	-772
Accumulated Other Comprehensive Income / (Loss)	382	418	739	-47	-87	282	-176	-467	-336	-538

This table presents Bio-Rad Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Total Assets	12,058	13,502	13,667	11,978	11,896	12,299	12,610	9,688	10,603	9,364
Total Current Assets	3,140	3,158	2,524	3,139	3,147	3,048	3,061	3,056	3,056	3,030
Cash & Equivalents	518	434	464	390	458	404	433	407	410	488
Restricted Cash	5.56	5.56	5.56	5.56	5.56	5.60	5.56	5.56	5.56	0.00
Short-Term Investments	1,332	1,356	1,387	1,333	1,301	1,203	1,212	1,209	1,212	1,176
Accounts Receivable	432	495	498	492	457	489	445	446	462	453
Inventories, net	686	719	-	777	776	781	783	804	804	760
Prepaid Expenses	147	124	121	123	124	140	143	153	133	123
Other Current Assets	19	24	48	20	25	26	39	32	28	31
Plant, Property, & Equipment, net	461	499	506	514	511	529	522	534	545	528
Total Noncurrent Assets	8,457	9,845	9,884	8,325	8,238	8,722	9,027	6,098	7,003	5,806
Long-Term Investments	7,459	8,831	8,879	7,311	7,218	7,698	8,018	5,100	6,003	4,839
Goodwill	400	406	408	412	407	414	413	412	415	411
Intangible Assets	325	332	328	329	314	321	314	307	307	294
Other Noncurrent Operating Assets	273	276	270	274	298	290	282	280	277	262
Total Liabilities & Shareholders' Equity	12,058	13,502	13,667	11,978	11,896	12,299	12,610	9,688	10,603	9,364
Total Liabilities	3,605	3,886	3,904	3,531	3,480	3,558	3,559	2,910	3,116	2,795
Total Current Liabilities	571	569	590	582	558	523	466	487	498	468
Short-Term Debt	0.45	0.47	0.52	0.48	0.48	0.50	0.49	0.48	1.26	1.20
Accounts Payable	143	135	161	150	112	145	103	127	122	122
Current Deferred & Payable Income Tax Liabilities	29	32	51	74	104	36	34	36	44	31
Current Employee Benefit Liabilities	192	195	174	155	155	140	146	132	146	124
Other Current Liabilities	206	206	203	203	187	202	182	191	185	189
Total Noncurrent Liabilities	3,034	3,318	3,314	2,949	2,922	3,035	3,093	2,423	2,618	2,327
Long-Term Debt	1,197	1,198	1,198	1,198	1,199	1,199	1,199	1,200	1,200	1,200
Noncurrent Deferred & Payable Income Tax Liabilities	1,485	1,770	1,770	1,402	1,370	1,476	1,541	878	1,076	818
Other Noncurrent Operating Liabilities	352	350	346	349	353	361	352	345	342	309
Commitments & Contingencies	-	0.00	-	-	-	0.00	-	-	-	0.00
Total Equity & Noncontrolling Interests	8,454	9,615	9,764	8,447	8,416	8,741	9,051	6,779	7,488	6,569
Total Preferred & Common Equity	8,454	9,615	9,764	8,447	8,416	8,741	9,051	6,779	7,488	6,569
Preferred Stock	-	-	-	-	-	0.00	-	0.00	0.00	0.00
Total Common Equity	8,454	9,615	9,764	8,448	8,417	8,741	9,051	6,779	7,488	6,569
Common Stock	431	447	463	474	439	449	463	475	448	463
Retained Earnings	9,047	9,898	9,967	8,805	8,911	9,261	9,645	7,479	8,132	7,416
Treasury Stock	-178	-264	-258	-458	-436	-633	-630	-724	-777	-772
Accumulated Other Comprehensive Income / (Loss)	-845	-467	-408	-373	-498	-336	-426	-451	-315	-538

This table displays calculated financial ratios and metrics derived from Bio-Rad Laboratories' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-7.15%	2.41%	4.45%	5.98%	0.97%	10.12%	14.81%	-4.12%	-4.67%	-3.92%
EBITDA Growth	9.01%	-61.24%	86.05%	344.15%	-52.76%	75.16%	18.09%	0.60%	-14.39%	-19.57%
EBIT Growth	9.01%	-61.24%	86.05%	344.15%	-52.76%	75.16%	18.09%	0.60%	-14.39%	-19.57%
NOPAT Growth	23.27%	-72.08%	327.61%	-149.45%	342.38%	82.93%	19.54%	-13.52%	-30.00%	-20.37%
Net Income Growth	22.95%	-76.20%	370.19%	199.07%	381.02%	116.88%	11.54%	-185.27%	82.43%	-189.38%
EPS Growth	21.64%	-76.28%	362.50%	197.30%	381.57%	117.04%	11.35%	-100.00%	0.00%	0.00%
Operating Cash Flow Growth	101.53%	28,980.22%	-108.20%	1,710.78%	-99.90%	205,153.33%	14.44%	-97.37%	2,030.11%	21.42%
Free Cash Flow Firm Growth	19.69%	-54.91%	-180.69%	717.28%	30.31%	96.44%	-8.08%	-209.41%	85.35%	-116.62%
Invested Capital Growth	-7.81%	-5.34%	17.78%	-39.52%	-56.36%	-259.50%	-135.94%	111.90%	238.15%	101.14%
Revenue Q/Q Growth	-1.35%	0.04%	2.36%	-0.19%	0.33%	6.95%	-1.92%	-0.09%	-1.81%	-0.53%
EBITDA Q/Q Growth	6.00%	-55.76%	154.50%	-66.95%	-53.39%	-52.73%	-90.73%	104.15%	-91.07%	22.65%
EBIT Q/Q Growth	6.00%	-55.76%	154.50%	-66.95%	-53.39%	-52.73%	-90.73%	104.15%	-91.07%	22.65%
NOPAT Q/Q Growth	5.91%	-66.28%	392.15%	-151.39%	536.06%	68.38%	-15.41%	0.16%	-6.47%	-12.09%
Net Income Q/Q Growth	6.42%	-72.45%	627.20%	-71.37%	366.91%	96.68%	-48.42%	39.75%	-300.07%	-136.83%
EPS Q/Q Growth	5.70%	-72.41%	653.70%	-71.39%	366.53%	8.22%	-36.17%	100.00%	100.00%	100.00%
Operating Cash Flow Q/Q Growth	100.57%	866.16%	-121.26%	1,681.86%	-99.95%	289.39%	12.67%	-97.38%	2,030.23%	21.41%
Free Cash Flow Firm Q/Q Growth	-1.70%	14.38%	-16.96%	-18.26%	134.50%	18.80%	-31.14%	19.21%	-377.54%	-112.08%
Invested Capital Q/Q Growth	-0.13%	-5.92%	3.10%	-4.69%	-36.39%	-97.65%	10.60%	-44.63%	-0.42%	19.71%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	55.54%	55.05%	54.98%	53.43%	54.38%	56.48%	56.05%	55.93%	53.42%	53.73%
EBITDA Margin	8.30%	3.14%	5.59%	23.44%	10.97%	17.44%	17.94%	18.82%	16.91%	14.15%
Operating Margin	8.26%	2.69%	5.52%	-4.51%	9.93%	16.55%	17.12%	17.22%	12.65%	10.48%
EBIT Margin	8.30%	3.14%	5.59%	23.44%	10.97%	17.44%	17.94%	18.82%	16.91%	14.15%
Profit (Net Income) Margin	5.41%	1.26%	5.66%	15.97%	76.08%	149.83%	145.57%	-129.45%	-23.86%	-71.86%
Tax Burden Percent	74.90%	62.56%	124.99%	71.32%	77.78%	77.56%	78.07%	77.11%	74.97%	78.73%
Interest Burden Percent	87.05%	64.00%	80.95%	95.53%	891.91%	1,107.55%	1,039.19%	-891.79%	-188.24%	-644.96%
Effective Tax Rate	25.10%	37.44%	-24.99%	28.68%	22.22%	22.44%	21.93%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	8.47%	2.53%	10.22%	-5.82%	26.08%	0.00%	0.00%	0.00%	57.93%	19.85%
ROIC Less NNEP Spread (ROIC-NNEP)	10.28%	3.30%	12.29%	-25.70%	-11.52%	0.00%	0.00%	0.00%	67.90%	50.16%
Return on Net Nonoperating Assets (RNNOA)	-3.80%	-1.51%	-5.79%	16.34%	9.90%	0.00%	0.00%	0.00%	-64.88%	-43.94%
Return on Equity (ROE)	4.67%	1.03%	4.44%	10.52%	35.98%	48.79%	36.11%	-31.14%	-6.94%	-24.09%
Cash Return on Invested Capital (CROIC)	16.60%	8.01%	-6.11%	43.43%	104.55%	0.00%	0.00%	-759.35%	-50.77%	-47.32%
Operating Return on Assets (OROA)	4.75%	1.72%	2.97%	10.86%	3.72%	4.23%	3.41%	3.37%	3.50%	3.35%
Return on Assets (ROA)	3.10%	0.69%	3.01%	7.40%	25.83%	36.36%	27.65%	-23.18%	-4.94%	-17.03%
Return on Common Equity (ROCE)	4.67%	1.03%	4.44%	10.52%	35.98%	48.79%	36.11%	-31.14%	-6.94%	-24.09%
Return on Equity Simple (ROE_SIMPLE)	4.39%	1.01%	4.17%	9.09%	30.56%	38.61%	31.09%	-37.73%	-7.29%	-28.07%
Net Operating Profit after Tax (NOPAT)	125	35	149	-74	179	327	391	338	236	188
NOPAT Margin	6.18%	1.69%	6.90%	-3.22%	7.73%	12.84%	13.37%	12.06%	8.85%	7.34%
Net Nonoperating Expense Percent (NNEP)	-1.81%	-0.76%	-2.07%	19.88%	37.60%	43.92%	29.96%	-32.13%	-9.96%	-30.31%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	3.12%	2.38%	2.42%
Cost of Revenue to Revenue	44.46%	44.95%	45.02%	46.57%	45.62%	43.52%	43.95%	44.07%	46.58%	46.27%
SG&A Expenses to Revenue	37.73%	39.39%	37.35%	36.46%	35.67%	31.38%	30.01%	29.54%	31.51%	31.72%
R&D to Revenue	9.56%	9.95%	11.58%	8.70%	8.77%	8.55%	8.92%	9.17%	9.26%	11.53%
Operating Expenses to Revenue	47.29%	52.35%	49.46%	57.94%	44.44%	39.93%	38.93%	38.71%	40.77%	43.25%
Earnings before Interest and Taxes (EBIT)	168	65	121	537	254	444	524	528	452	363
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	168	65	121	537	254	444	524	528	452	363
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.63	2.09	2.42	1.73	1.92	1.76	1.65	1.30	1.08	1.40
Price to Tangible Book Value (P/TBV)	2.28	2.78	3.16	1.90	2.07	1.85	1.73	1.41	1.18	1.57
Price to Revenue (P/Rev)	2.01	2.60	3.29	3.04	4.79	6.83	7.73	4.48	3.52	3.58
Price to Earnings (P/E)	37.20	207.11	58.11	19.03	6.30	4.56	5.31	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.69%	0.48%	1.72%	5.25%	15.88%	21.93%	18.82%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.11	3.10	3.65	4.08	13.85	0.00	0.00	16.70	2.06	3.07
Enterprise Value to Revenue (EV/Rev)	1.48	2.00	2.66	1.70	2.49	2.69	2.52	1.11	0.49	1.52
Enterprise Value to EBITDA (EV/EBITDA)	17.83	63.82	47.60	7.25	22.74	15.42	14.02	5.90	2.88	10.72
Enterprise Value to EBIT (EV/EBIT)	17.83	63.82	47.60	7.25	22.74	15.42	14.02	5.90	2.88	10.72
Enterprise Value to NOPAT (EV/NOPAT)	23.92	118.90	38.58	0.00	32.28	20.95	18.83	9.21	5.50	20.69
Enterprise Value to Operating Cash Flow (EV/OCF)	4,020.67	19.18	0.00	13.63	20,230.28	11.70	10.98	176.81	3.47	8.56
Enterprise Value to Free Cash Flow (EV/FCFF)	12.21	37.56	0.00	7.08	8.05	4.87	5.69	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.17	0.17	0.15	0.11	0.08	0.00	0.00	0.12	0.14	0.18
Long-Term Debt to Equity	0.17	0.17	0.15	0.11	0.00	0.00	0.00	0.12	0.14	0.18
Financial Leverage	-0.37	-0.46	-0.47	-0.64	-0.86	-1.02	-1.09	-1.06	-0.96	-0.88
Leverage Ratio	1.51	1.49	1.47	1.42	1.39	1.34	1.31	1.34	1.41	1.41
Compound Leverage Factor	1.31	0.95	1.19	1.36	12.43	14.86	13.57	-11.98	-2.65	-9.13
Debt to Total Capital	14.85%	14.42%	12.93%	9.85%	7.10%	0.14%	0.08%	11.08%	12.07%	15.46%
Short-Term Debt to Total Capital	0.01%	0.01%	0.01%	0.01%	6.88%	0.02%	0.00%	0.00%	0.01%	0.02%
Long-Term Debt to Total Capital	14.84%	14.41%	12.91%	9.84%	0.22%	0.12%	0.08%	11.08%	12.06%	15.45%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.12%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	85.15%	85.58%	87.07%	90.15%	92.90%	99.86%	99.92%	88.92%	87.93%	84.54%
Debt to EBITDA	2.59	6.69	3.60	0.82	1.73	0.03	0.02	2.27	2.66	3.31
Net Debt to EBITDA	-6.42	-19.10	-11.20	-5.71	-20.98	-23.74	-29.09	-17.87	-17.96	-14.60
Long-Term Debt to EBITDA	2.59	6.69	3.60	0.82	0.05	0.03	0.02	2.27	2.66	3.31
Debt to NOPAT	3.48	12.47	2.92	-5.96	2.46	0.04	0.03	3.55	5.07	6.38
Net Debt to NOPAT	-8.62	-35.58	-9.08	41.61	-29.77	-32.27	-39.04	-27.91	-34.30	-28.16
Long-Term Debt to NOPAT	3.47	12.46	2.92	-5.96	0.08	0.04	0.03	3.55	5.07	6.37
Altman Z-Score	3.81	4.23	4.79	4.61	4.49	4.82	4.71	3.53	3.23	3.81
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.03	3.91	3.93	4.49	2.41	3.39	2.92	5.55	5.83	6.48
Quick Ratio	2.67	2.57	2.43	2.74	1.64	2.23	1.90	4.02	4.01	4.53
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	245	110	-89	550	716	1,407	1,293	-1,415	-207	-449
Operating Cash Flow to CapEx	0.64%	153.20%	-15.41%	227.47%	0.29%	539.17%	500.74%	15.63%	239.55%	275.05%
Free Cash Flow to Firm to Interest Expense	11.28	4.72	-3.87	22.94	30.58	64.35	833.69	-37.13	-4.20	-9.18
Operating Cash Flow to Interest Expense	0.03	9.24	-0.77	11.91	0.01	26.76	431.63	0.46	7.59	9.31
Operating Cash Flow Less CapEx to Interest Expense	-5.33	3.21	-5.77	6.68	-4.19	21.80	345.44	-2.49	4.42	5.92
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.57	0.55	0.53	0.46	0.34	0.24	0.19	0.18	0.21	0.24
Accounts Receivable Turnover	5.25	5.42	5.16	5.34	6.04	6.43	6.93	6.10	5.43	5.45
Inventory Turnover	1.87	1.83	1.74	1.81	1.85	1.88	2.15	1.91	1.66	1.54
Fixed Asset Turnover	4.66	4.47	4.40	4.57	4.59	5.14	5.83	5.55	5.20	4.86
Accounts Payable Turnover	7.15	7.28	7.25	8.28	9.19	8.99	9.13	8.92	8.90	8.90
Days Sales Outstanding (DSO)	69.51	67.40	70.73	68.34	60.39	56.77	52.64	59.80	67.20	66.95
Days Inventory Outstanding (DIO)	195.40	199.27	210.15	201.73	196.89	193.79	169.72	190.87	219.98	236.73
Days Payable Outstanding (DPO)	51.02	50.15	50.35	44.10	39.71	40.61	39.98	40.93	41.01	41.01
Cash Conversion Cycle (CCC)	213.88	216.52	230.53	225.97	217.57	209.96	182.38	209.74	246.17	262.66
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,414	1,339	1,577	954	416	-664	-1,566	186	630	1,267
Invested Capital Turnover	1.37	1.50	1.48	1.81	3.38	-20.56	-2.62	-4.06	6.54	2.71
Increase / (Decrease) in Invested Capital	-120	-75	238	-623	-538	-1,080	-902	1,753	444	637
Enterprise Value (EV)	2,987	4,145	5,750	3,891	5,766	6,846	7,354	3,112	1,299	3,895
Market Capitalization	4,063	5,385	7,104	6,958	11,077	17,389	22,605	12,541	9,411	9,197
Book Value per Share	$84.98	$87.31	$98.45	$134.18	$192.25	$331.20	$457.42	$322.40	$299.92	$234.65
Tangible Book Value per Share	$60.76	$65.69	$75.60	$122.40	$178.57	$314.73	$437.32	$297.63	$274.73	$209.50
Total Capital	2,925	3,014	3,365	4,460	6,195	9,894	13,696	10,813	9,941	7,771
Total Debt	434	435	435	439	440	14	11	1,198	1,200	1,202
Total Long-Term Debt	434	434	435	439	14	12	11	1,198	1,199	1,200
Net Debt	-1,076	-1,240	-1,353	-3,067	-5,319	-10,544	-15,251	-9,429	-8,111	-5,302
Capital Expenditures (CapEx)	116	141	115	126	98	108	134	113	157	166
Debt-free, Cash-free Net Working Capital (DFCFNWC)	546	530	714	723	581	513	435	794	913	899
Debt-free Net Working Capital (DFNWC)	1,337	1,374	1,474	1,573	1,701	1,510	1,310	2,590	2,526	2,564
Net Working Capital (NWC)	1,336	1,373	1,474	1,573	1,275	1,508	1,310	2,589	2,526	2,563
Net Nonoperating Expense (NNE)	16	8.86	27	-439	-1,580	-3,487	-3,864	3,965	874	2,033
Net Nonoperating Obligations (NNO)	-1,076	-1,240	-1,353	-3,067	-5,339	-10,544	-15,251	-9,429	-8,111	-5,302
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	27.04%	25.60%	33.05%	31.57%	25.12%	20.17%	14.87%	28.32%	34.19%	35.04%
Debt-free Net Working Capital to Revenue	66.18%	66.41%	68.25%	68.72%	73.58%	59.32%	44.83%	92.42%	94.56%	99.89%
Net Working Capital to Revenue	66.17%	66.40%	68.23%	68.69%	55.14%	59.25%	44.81%	92.40%	94.55%	99.84%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.87	$0.96	$4.12	$12.25	$58.93	$127.86	$142.33	($121.79)	($21.82)	($65.36)
Adjusted Weighted Average Basic Shares Outstanding	29.19M	29.44M	29.66M	29.84M	29.84M	29.77M	29.83M	29.79M	29.21M	28.21M
Adjusted Diluted Earnings per Share	$3.85	$0.95	$4.07	$12.10	$58.27	$126.20	$140.56	($121.79)	($21.82)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	29.41M	29.65M	30.03M	30.23M	30.18M	30.16M	30.21M	29.79M	29.21M	28.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	29.36M	29.58M	0.00	29.80M	29.93M	29.84M	29.93M	29.60M	28.52M	28.01M
Normalized Net Operating Profit after Tax (NOPAT)	125	74	92	135	179	327	391	338	236	188
Normalized NOPAT Margin	6.18%	3.57%	4.24%	5.89%	7.73%	12.84%	13.37%	12.06%	8.85%	7.34%
Pre Tax Income Margin	7.22%	2.01%	4.53%	22.39%	97.81%	193.19%	186.45%	-167.88%	-31.82%	-91.27%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	7.72	2.78	5.25	22.39	10.83	20.31	338.08	13.85	9.14	7.43
NOPAT to Interest Expense	5.76	1.49	6.48	-3.08	7.63	14.95	251.86	8.87	4.79	3.85
EBIT Less CapEx to Interest Expense	2.36	-3.25	0.25	17.16	6.62	15.35	251.88	10.89	5.97	4.04
NOPAT Less CapEx to Interest Expense	0.40	-4.54	1.48	-8.31	3.43	9.98	165.66	5.91	1.62	0.47
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	2.39%	13.38%	1.59%	2.62%	1.18%	-5.95%	-67.27%	-11.04%

This table displays calculated financial ratios and metrics derived from Bio-Rad Laboratories' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-8.87%	-0.35%	-3.32%	-1.45%	-7.15%	-6.73%	-9.75%	-6.26%	2.79%	-2.00%
EBITDA Growth	-103.90%	190.56%	102.23%	-23.03%	176.41%	-73.11%	418.04%	-86.42%	484.48%	3.96%
EBIT Growth	-103.90%	190.56%	102.23%	-23.03%	176.41%	-73.11%	418.04%	-86.42%	484.48%	3.96%
NOPAT Growth	-45.98%	9.06%	-50.89%	-27.08%	6.39%	-13.53%	-30.56%	13.26%	-30.67%	-47.53%
Net Income Growth	-104.14%	152.88%	102.05%	-25.63%	165.27%	-57.75%	456.71%	-86.32%	514.71%	-304.67%
EPS Growth	-104.22%	327.63%	102.06%	0.00%	166.42%	-71.50%	479.74%	-92.62%	541.21%	17.37%
Operating Cash Flow Growth	0.00%	-97.38%	-100.00%	53.39%	0.00%	2,030.11%	0.00%	0.99%	-0.99%	21.42%
Free Cash Flow Firm Growth	-231.42%	-268.80%	145.27%	56.43%	88.84%	77.99%	-669.37%	-19.70%	-67.02%	-63.00%
Invested Capital Growth	119.21%	111.90%	-35.57%	931.51%	88.03%	238.15%	210.48%	107.43%	67.31%	101.14%
Revenue Q/Q Growth	-1.49%	7.26%	-7.32%	0.63%	-7.19%	7.75%	-10.33%	4.53%	1.76%	2.73%
EBITDA Q/Q Growth	83.82%	3,318.23%	-98.46%	-1,631.49%	110.05%	1,032.45%	-70.27%	-651.11%	131.50%	101.43%
EBIT Q/Q Growth	83.82%	3,318.23%	-98.46%	-1,631.49%	110.05%	1,032.45%	-70.27%	-651.11%	131.50%	101.43%
NOPAT Q/Q Growth	-22.98%	35.84%	-44.08%	24.64%	12.36%	10.40%	-55.08%	103.27%	-31.21%	-16.45%
Net Income Q/Q Growth	82.40%	608.43%	-91.67%	-1,785.35%	109.14%	229.14%	9.78%	-664.05%	130.16%	-209.59%
EPS Q/Q Growth	0.00%	2,252.92%	160.89%	-1,806.47%	109.19%	823.90%	13.89%	-666.99%	130.61%	69.11%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-100.00%	0.00%	200.00%	1,492.95%	-100.00%	0.00%	200.00%	1,853.56%
Free Cash Flow Firm Q/Q Growth	-81.73%	17.78%	111.33%	-357.36%	53.45%	-62.10%	-193.25%	45.90%	35.04%	-58.19%
Invested Capital Q/Q Growth	472.38%	-44.63%	-382.45%	215.23%	4.34%	-0.42%	-7.70%	116.34%	-15.84%	19.71%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.72%	54.37%	53.55%	53.22%	53.10%	53.78%	53.37%	55.62%	54.78%	51.22%
EBITDA Margin	-28.74%	862.27%	14.36%	-218.48%	23.65%	248.56%	82.41%	-434.47%	134.49%	263.69%
Operating Margin	13.90%	16.25%	9.15%	13.16%	14.39%	13.99%	7.32%	15.90%	9.92%	8.74%
EBIT Margin	-28.74%	862.27%	14.36%	-218.48%	23.65%	248.56%	82.41%	-434.47%	134.49%	263.69%
Profit (Net Income) Margin	-23.91%	113.36%	10.19%	-170.64%	16.81%	51.35%	62.85%	-339.16%	100.53%	-107.24%
Tax Burden Percent	78.53%	75.85%	81.30%	77.46%	77.50%	81.64%	78.18%	77.72%	75.81%	78.75%
Interest Burden Percent	105.96%	17.33%	87.30%	100.83%	91.71%	25.30%	97.56%	100.44%	98.61%	-51.64%
Effective Tax Rate	0.00%	24.15%	18.70%	0.00%	22.50%	18.36%	21.82%	0.00%	24.19%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	76.68%	62.60%	74.77%	540.51%	30.59%	22.95%	16.55%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	91.35%	62.15%	71.67%	536.79%	64.07%	14.45%	27.83%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	-87.85%	-58.58%	-68.48%	-535.22%	-56.23%	-12.91%	-24.38%
Return on Equity (ROE)	-50.62%	-31.14%	-1.92%	-11.17%	4.02%	6.29%	5.29%	-25.63%	10.04%	-7.83%
Cash Return on Invested Capital (CROIC)	-520.42%	-759.35%	0.00%	-87.86%	-8.96%	-50.77%	-151.91%	-44.92%	-25.03%	-47.32%
Operating Return on Assets (OROA)	-5.04%	154.39%	2.85%	-49.06%	5.37%	51.47%	16.34%	-102.77%	30.85%	62.48%
Return on Assets (ROA)	-4.19%	20.30%	2.02%	-38.32%	3.82%	10.63%	12.46%	-80.23%	23.06%	-25.41%
Return on Common Equity (ROCE)	-50.62%	-31.14%	-1.92%	-11.17%	4.02%	6.29%	5.29%	-25.63%	10.04%	-7.83%
Return on Equity Simple (ROE_SIMPLE)	-71.22%	0.00%	-1.96%	-5.07%	-1.89%	0.00%	-3.56%	-19.56%	-10.40%	0.00%
Net Operating Profit after Tax (NOPAT)	66	90	50	63	70	78	35	71	49	41
NOPAT Margin	9.73%	12.32%	7.44%	9.21%	11.15%	11.42%	5.72%	11.13%	7.52%	6.12%
Net Nonoperating Expense Percent (NNEP)	-1.82%	5.98%	0.18%	-14.67%	0.45%	3.10%	3.72%	-33.48%	8.50%	-11.28%
Return On Investment Capital (ROIC_SIMPLE)	-	0.83%	-	-	-	0.78%	-	-	-	0.53%
Cost of Revenue to Revenue	45.28%	45.63%	46.45%	46.78%	46.90%	46.22%	46.63%	44.38%	45.22%	48.78%
SG&A Expenses to Revenue	31.01%	29.06%	33.32%	30.51%	31.83%	30.41%	35.18%	30.50%	30.85%	30.56%
R&D to Revenue	9.81%	9.07%	11.07%	9.55%	6.89%	9.38%	10.87%	9.23%	14.01%	11.93%
Operating Expenses to Revenue	40.82%	38.13%	44.40%	40.06%	38.72%	39.79%	46.05%	39.72%	44.86%	42.49%
Earnings before Interest and Taxes (EBIT)	-196	6,297	97	-1,488	150	1,693	503	-2,774	874	1,760
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-196	6,297	97	-1,488	150	1,693	503	-2,774	874	1,760
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.47	1.30	1.45	1.33	1.24	1.08	1.09	1.15	1.25	1.40
Price to Tangible Book Value (P/TBV)	1.60	1.41	1.57	1.46	1.35	1.18	1.18	1.29	1.38	1.57
Price to Revenue (P/Rev)	4.42	4.48	5.10	4.05	3.83	3.52	3.79	3.04	3.61	3.58
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	12.69	16.70	0.00	5.58	4.17	2.06	2.40	1.80	2.74	3.07
Enterprise Value to Revenue (EV/Rev)	1.52	1.11	1.67	1.22	0.97	0.49	0.54	0.89	1.12	1.52
Enterprise Value to EBITDA (EV/EBITDA)	0.00	5.90	0.93	0.72	0.52	2.88	1.63	0.00	9.78	10.72
Enterprise Value to EBIT (EV/EBIT)	0.00	5.90	0.93	0.72	0.52	2.88	1.63	0.00	9.78	10.72
Enterprise Value to NOPAT (EV/NOPAT)	12.66	9.21	16.65	13.25	10.44	5.50	6.21	9.75	13.52	20.69
Enterprise Value to Operating Cash Flow (EV/OCF)	6.36	176.81	0.00	0.00	149.94	3.47	3.72	6.05	7.72	8.56
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	11.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.14	0.12	0.12	0.14	0.14	0.14	0.13	0.18	0.16	0.18
Long-Term Debt to Equity	0.14	0.12	0.12	0.14	0.14	0.14	0.13	0.18	0.16	0.18
Financial Leverage	-1.06	-1.06	-1.05	-0.96	-0.94	-0.96	-1.00	-0.88	-0.89	-0.88
Leverage Ratio	1.35	1.34	1.41	1.42	1.42	1.41	1.40	1.42	1.41	1.41
Compound Leverage Factor	1.43	0.23	1.23	1.43	1.30	0.36	1.36	1.43	1.40	-0.73
Debt to Total Capital	12.41%	11.08%	10.93%	12.43%	12.47%	12.07%	11.70%	15.04%	13.83%	15.46%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.01%	0.01%	0.00%	0.01%	0.01%	0.02%
Long-Term Debt to Total Capital	12.41%	11.08%	10.93%	12.42%	12.47%	12.06%	11.70%	15.04%	13.81%	15.45%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	87.59%	88.92%	89.07%	87.58%	87.54%	87.93%	88.30%	84.96%	86.17%	84.54%
Debt to EBITDA	-0.09	2.27	0.24	0.25	0.24	2.66	1.40	-2.80	4.06	3.31
Net Debt to EBITDA	0.64	-17.87	-1.91	-1.66	-1.54	-17.96	-9.87	12.89	-21.71	-14.60
Long-Term Debt to EBITDA	-0.09	2.27	0.24	0.25	0.24	2.66	1.40	-2.80	4.05	3.31
Debt to NOPAT	3.55	3.55	4.30	4.69	4.74	5.07	5.35	5.16	5.61	6.38
Net Debt to NOPAT	-24.07	-27.91	-34.22	-30.70	-30.79	-34.30	-37.74	-23.72	-30.02	-28.16
Long-Term Debt to NOPAT	3.55	3.55	4.30	4.69	4.74	5.07	5.34	5.16	5.60	6.37
Altman Z-Score	3.55	4.94	3.60	3.01	3.38	3.56	3.32	2.33	3.67	4.31
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	-0.01%	-0.01%	0.00%	0.00%	-0.01%	-0.01%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.50	5.55	4.28	5.39	5.64	5.83	6.57	6.28	6.14	6.48
Quick Ratio	4.00	4.02	3.99	3.80	3.97	4.01	4.48	4.23	4.19	4.53
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2,022	-1,663	188	-485	-226	-366	-1,073	-580	-377	-596
Operating Cash Flow to CapEx	0.00%	50.68%	0.00%	-68.02%	53.48%	889.04%	0.00%	-55.20%	58.00%	1,059.52%
Free Cash Flow to Firm to Interest Expense	-173.38	-142.48	15.27	-39.28	-18.21	-29.69	-87.37	-47.32	-30.97	-48.94
Operating Cash Flow to Interest Expense	0.00	1.51	0.00	-1.91	1.90	30.43	0.00	-1.90	1.91	37.36
Operating Cash Flow Less CapEx to Interest Expense	0.00	-1.47	-2.90	-4.71	-1.65	27.00	-3.27	-5.34	-1.39	33.83
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.18	0.18	0.20	0.22	0.23	0.21	0.20	0.24	0.23	0.24
Accounts Receivable Turnover	6.60	6.10	5.78	5.88	6.12	5.43	5.52	5.47	5.61	5.45
Inventory Turnover	1.94	1.91	0.00	1.78	1.73	1.66	0.00	1.49	1.49	1.54
Fixed Asset Turnover	5.98	5.55	5.60	5.62	5.59	5.20	5.06	4.89	4.88	4.86
Accounts Payable Turnover	8.86	8.92	7.78	8.28	9.92	8.90	9.21	8.54	10.06	8.90
Days Sales Outstanding (DSO)	55.31	59.80	63.20	62.08	59.69	67.20	66.06	66.74	65.03	66.95
Days Inventory Outstanding (DIO)	188.21	190.87	0.00	205.30	211.26	219.98	0.00	244.52	245.03	236.73
Days Payable Outstanding (DPO)	41.21	40.93	46.89	44.07	36.80	41.01	39.62	42.74	36.29	41.01
Cash Conversion Cycle (CCC)	202.31	209.74	16.31	223.31	234.15	246.17	26.44	268.51	273.76	262.66
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	336	186	-526	606	633	630	581	1,258	1,059	1,267
Invested Capital Turnover	-3.96	-4.06	-6.08	8.33	5.61	6.54	94.46	2.75	3.05	2.71
Increase / (Decrease) in Invested Capital	2,088	1,753	-138	548	296	444	1,108	651	426	637
Enterprise Value (EV)	4,271	3,112	4,640	3,385	2,639	1,299	1,394	2,269	2,896	3,895
Market Capitalization	12,388	12,541	14,177	11,225	10,422	9,411	9,864	7,790	9,325	9,197
Book Value per Share	$284.66	$322.40	$329.90	$285.32	$289.49	$299.92	$317.38	$237.65	$268.66	$234.65
Tangible Book Value per Share	$260.25	$297.63	$305.05	$260.32	$264.69	$274.73	$291.91	$212.43	$242.74	$209.50
Total Capital	9,651	10,813	10,962	9,646	9,615	9,941	10,251	7,979	8,689	7,771
Total Debt	1,198	1,198	1,199	1,199	1,199	1,200	1,200	1,200	1,201	1,202
Total Long-Term Debt	1,197	1,198	1,198	1,198	1,199	1,199	1,199	1,200	1,200	1,200
Net Debt	-8,117	-9,429	-9,537	-7,841	-7,784	-8,111	-8,470	-5,521	-6,429	-5,302
Capital Expenditures (CapEx)	28	35	36	35	44	42	40	42	40	43
Debt-free, Cash-free Net Working Capital (DFCFNWC)	714	794	78	829	825	913	944	948	931	899
Debt-free Net Working Capital (DFNWC)	2,570	2,590	1,935	2,557	2,589	2,526	2,595	2,570	2,559	2,564
Net Working Capital (NWC)	2,569	2,589	1,935	2,557	2,589	2,526	2,595	2,569	2,558	2,563
Net Nonoperating Expense (NNE)	229	-738	-19	1,225	-36	-272	-349	2,237	-604	757
Net Nonoperating Obligations (NNO)	-8,117	-9,429	-10,290	-7,841	-7,784	-8,111	-8,470	-5,521	-6,429	-5,302
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	25.47%	28.32%	2.81%	29.94%	30.31%	34.19%	36.24%	37.00%	36.08%	35.04%
Debt-free Net Working Capital to Revenue	91.63%	92.42%	69.64%	92.36%	95.17%	94.56%	99.62%	100.28%	99.18%	99.89%
Net Working Capital to Revenue	91.61%	92.40%	69.62%	92.34%	95.16%	94.55%	99.60%	100.26%	99.13%	99.84%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.52)	$27.24	$2.33	($39.59)	$3.65	$11.79	$13.46	($76.26)	$23.37	($25.93)
Adjusted Weighted Average Basic Shares Outstanding	29.73M	29.79M	29.60M	29.36M	29.10M	29.21M	28.52M	28.40M	27.95M	28.21M
Adjusted Diluted Earnings per Share	($5.52)	$117.98	$2.32	$0.00	$3.64	$33.63	$13.45	($76.26)	$23.34	$39.47
Adjusted Weighted Average Diluted Shares Outstanding	29.73M	29.79M	29.75M	29.36M	29.22M	29.21M	28.54M	28.40M	27.99M	28.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	29.82M	29.60M	29.61M	29.08M	29.15M	28.52M	28.52M	27.87M	28.00M	28.01M
Normalized Net Operating Profit after Tax (NOPAT)	66	90	50	63	70	78	35	71	49	41
Normalized NOPAT Margin	9.73%	12.32%	7.44%	9.21%	11.15%	11.42%	5.72%	11.13%	7.52%	6.12%
Pre Tax Income Margin	-30.45%	149.45%	12.53%	-220.29%	21.69%	62.90%	80.40%	-436.40%	132.61%	-136.17%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-16.78	539.60	7.88	-120.56	12.06	137.40	41.00	-226.19	71.78	144.45
NOPAT to Interest Expense	5.68	7.71	4.08	5.08	5.69	6.32	2.85	5.79	4.01	3.35
EBIT Less CapEx to Interest Expense	-19.14	536.63	4.98	-123.36	8.51	133.98	37.73	-229.63	68.48	140.92
NOPAT Less CapEx to Interest Expense	3.32	4.74	1.18	2.28	2.14	2.89	-0.42	2.35	0.71	-0.18
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-2.08%	-5.95%	0.00%	-69.59%	-200.51%	-67.27%	-134.47%	-24.67%	-51.83%	-11.04%

Frequently Asked Questions About Bio-Rad Laboratories' Financials

When does Bio-Rad Laboratories's fiscal year end?

According to the most recent income statement we have on file, Bio-Rad Laboratories' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Bio-Rad Laboratories' net income changed over the last 9 years?

Bio-Rad Laboratories' net income appears to be on a downward trend, with a most recent value of -$1.84 billion in 2024, falling from $109.24 million in 2015. The previous period was -$637.30 million in 2023.

What is Bio-Rad Laboratories's operating income?

Bio-Rad Laboratories's total operating income in 2024 was $269 million, based on the following breakdown:

Total Gross Profit: $1.38 billion
Total Operating Expenses: $1.11 billion

How has Bio-Rad Laboratories revenue changed over the last 9 years?

Over the last 9 years, Bio-Rad Laboratories' total revenue changed from $2.02 billion in 2015 to $2.57 billion in 2024, a change of 27.1%.

How much debt does Bio-Rad Laboratories have?

Bio-Rad Laboratories' total liabilities were at $2.79 billion at the end of 2024, a 21.4% decrease from 2023, and a 129.2% increase since 2015.

How much cash does Bio-Rad Laboratories have?

In the past 9 years, Bio-Rad Laboratories' cash and equivalents has ranged from $383.82 million in 2017 to $662.21 million in 2020, and is currently $488.10 million as of their latest financial filing in 2024.

How has Bio-Rad Laboratories' book value per share changed over the last 9 years?

Over the last 9 years, Bio-Rad Laboratories' book value per share changed from 84.98 in 2015 to 234.65 in 2024, a change of 176.1%.

Related Companies

This page (NYSE:BIO.B) was last updated on 5/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Rad Laboratories (BIO.B) Financials

Frequently Asked Questions About Bio-Rad Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Rad Laboratories (BIO.B) Financials

Annual Income Statements for Bio-Rad Laboratories

Quarterly Income Statements for Bio-Rad Laboratories

Annual Cash Flow Statements for Bio-Rad Laboratories

Quarterly Cash Flow Statements for Bio-Rad Laboratories

Annual Balance Sheets for Bio-Rad Laboratories

Quarterly Balance Sheets for Bio-Rad Laboratories

Annual Metrics and Ratios for Bio-Rad Laboratories

Quarterly Metrics and Ratios for Bio-Rad Laboratories

Frequently Asked Questions About Bio-Rad Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools